Inductos

Dibotermin alfa, the active ingredient in Inductos, is a recombinant human bone morphogenetic protein presented as an implant for implantation use. It promotes bone formation and is employed in spinal fusion surgery and orthopedic bone repair procedures in patients requiring enhanced osteogenesis.

GNH USA supplies Inductos as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals and orthopedic surgery centres worldwide. The company adheres to stringent quality standards and provides regulatory support for global distribution. Clients benefit from reliable logistics, temperature‑controlled shipping where required, and responsive technical assistance.

Inductos (dibotermin alfa) is used in orthopedic and spinal procedures that rely on bone morphogenetic protein pathways to enhance bone healing. - Spinal fusion surgery: promotes successful vertebral fusion and reduces time to solid bone union. - Orthopedic bone repair: stimulates bone regeneration in complex fracture sites. - Long bone non‑union: supports bridging bone formation in difficult fracture non‑unions. - Cervical spine fusion: facilitates fusion of cervical vertebrae during stabilization procedures.

Inductos may be associated with a range of adverse reactions following implantation.

Common Side Effects: - Local swelling at the implant site. - Post‑operative pain or discomfort. - Seroma formation around the device. - Mild inflammatory response. - Transient fever. - Ectopic bone formation near the implant.

Serious or Rare Side Effects: - Severe infection requiring surgical intervention. - Allergic or hypersensitivity reaction. - Neurological impairment due to ectopic bone encroachment. - Deep wound dehiscence. - Systemic inflammatory response syndrome. - Malignant transformation (extremely rare).

Prior to using Inductos, clinicians should consider several safety measures. - Patient selection: evaluate for active infection at the intended implantation site. - Allergy assessment: confirm no known hypersensitivity to recombinant BMPs. - Implant site preparation: ensure adequate vascularity and stable fixation. - Monitoring: obtain serial radiographs to assess appropriate bone growth. - Contraindications: avoid in patients with known malignancy at the implantation area. - Store at 2-8°C: keep refrigerated, protect from light, do not freeze or shake.

Inductos may interact with other therapies that influence bone metabolism or wound healing.

Major Interactions (Avoid): - High‑dose systemic corticosteroids: may markedly suppress BMP‑induced bone formation. - Concurrent use of other osteogenic agents: risk of excessive ectopic bone growth.

Moderate Interactions (Monitor Closely): - Non‑steroidal anti‑inflammatory drugs (NSAIDs): can reduce osteogenic efficacy. - Anticoagulants: may increase peri‑operative bleeding risk. - Radiation therapy: may impair local bone healing response. - Chemotherapy agents: could diminish osteoblast activity. - Immunosuppressants: heightened infection susceptibility at the implant site.